MELA Sciences, Inc., a Leader in the Fight Against Melanoma, Participates in the Washington D.C. Dermatological Society's Fall

MELA Sciences, Inc., a Leader in the Fight Against Melanoma, Participates in
the Washington D.C. Dermatological Society's Fall Clinical Conference

IRVINGTON, N.Y., Oct. 25, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc.
(Nasdaq:MELA), the medical device company that has developed and is
commercializing MelaFind®, the first and only FDA approved optical diagnostic
device for melanoma detection used by dermatologists in their fight against
melanoma, today announced that the company will be participating in the
Washington D.C. Dermatological Society's Fall Clinical Conference taking place
October 26, 2013 in Falls Church, Virginia.

The Washington D.C. Dermatological Society's Fall Clinical Conference is a
half-day medical meeting that is well attended by approximately 100
dermatologists, as well as physician assistants and nurse practitioners who
specialize in dermatology. The Program Director and Moderator of the
conference will be Amir A. Bajoghli, MD, Assistant Clinical Professor of
Dermatology at Georgetown University and Chief of Dermatology at INOVA Fairfax

The conference is a hands-on symposium involving live patient case studies and
pathology analysis. This interactive activity provides physicians with
practical information regarding rare dermatologic conditions, as well as
common problems that manifest themselves in unique ways. Attendees will also
evaluate diagnostic testing and imaging in dermatology. Physicians and other
health care providers will have the opportunity to consider current standards
of care, as well as recommendations for optimizing patient care. The
overreaching goal for this conference is to update the practicing
dermatologist and generalist in topics that will improve patient care.

"We are pleased to have MELA Sciences attending our conference, and look
forward to learning more about the company and working with their digital,
spectral imaging system, MelaFind," said Dr. Bajoghli. While we believe
MelaFind will be a valuable tool when making biopsy decisions, we are also
focused on exploring the value of providing these images to our
dermatopathologists as these atypical lesions are being assessed for biopsy.
The ability for the first time to image up to 2.5 mm below a lesion should
provide additional information, which can then be used in determining a proper
course of diagnosis and subsequent treatment."

According to the Skin Cancer Foundation, melanoma is currently the deadliest
and fastest growing cancer in the U.S., with one American dying from melanoma
every hour. Skin cancer has reached epidemic proportions, even though the
cause (ultraviolet rays) and prevention (sun protection) is known. Melanoma is
almost 100% curable if caught early, but according to a Harris Interactive
Study commissioned by MELA Sciences only 24 percent of American adults have
had a skin check by a dermatologist, which can lead to missed cases as well as
potentially advanced and fatal stages.

MelaFind® is the first and only FDA-approved optical imaging device for
melanoma detection used by dermatologists and was recognized by the Cleveland
Clinic as a Top 10 Medical Innovation for 2013. MelaFind® was featured in the
Wall Street Journal, and recently received national attention on "The Rachael
Ray Show". Consumers can learn more about the device or locate a MelaFind®
dermatologist in their area by visiting

About MELA Sciences, Inc.

MELA Sciences, Inc. is a medical device company focused on the
commercialization of its flagship product, MelaFind® and its further design
and development. MelaFind® is a non-invasive tool that provides additional
information to dermatologists during melanoma skin examinations. The device
uses light from visible to near-infrared wavelengths to evaluate skin lesions
up to 2.5 mm beneath the skin. The device supplies information on a lesion's
level of morphologic disorganization to provide additional objective
information that may be used by dermatologists in the biopsy decision-making
process. MelaFind® has been approved by the U.S. Food and Drug Administration
for use in the U.S. In addition, MelaFind® has received CE Mark approval and
is approved for use in the European Union.

For more information on MELA Sciences, Inc., visit

Safe Harbor:

This press release includes "forward-looking statements" within the meaning of
the Securities Litigation Reform Act of 1995. These statements include but are
not limited to our plans, objectives, expectations and intentions and other
statements that contain words such as "expects," "contemplates,"
"anticipates," "plans," "intends," "believes," "assumes," "predicts" and
variations of such words or similar expressions that predict or indicate
future events or trends, or that do not relate to historical matters. These
statements are based on our current beliefs or expectations and are inherently
subject to significant known and unknown uncertainties and changes in
circumstances, many of which are beyond our control. There can be no assurance
that our beliefs or expectations will be achieved. Actual results may differ
materially from our beliefs or expectations due to financial, economic,
business, competitive, market, regulatory and political factors or conditions
affecting the company and the medical device industry in general, as well as
more specific risks and uncertainties facing the company such as those set
forth in its reports on Forms 10-Q and 10-K filed with the U.S. Securities and
Exchange Commission (the "SEC"). Factors that might cause such a difference
include whether MelaFind® achieves market acceptance. Given the uncertainties
affecting companies in the medical device industry such as the Company, any or
all of these forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such factors or forward-looking statements. The
Company urges you to carefully review and consider the disclosures found in
its filings with the SEC which are available at and

CONTACT: For further information contact:
         Lynn Pieper
         Westwicke Partners
         Erica Sperling
         Rpr Marketing Communications
Press spacebar to pause and continue. Press esc to stop.